Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Rangering i aksjer #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Aksjekurs
$0.00023723
Sist synkronisert: 2024-08-26
Markedsverdi
$1.41K
Endring (1 dag)
111.67%
Endring (1 år)
0.00%
Land
FR
Handel Pharnext S.A. (ALPHA)

Kategori

Inntekter for Pharnext S.A. (ALPHA)
Inntekter i Dec 2023 TTM: $-31.69M
Ifølge Pharnext S.A. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-31.69M. I 2022 hadde selskapet et resultat på $-43.29M, en nedgang sammenlignet med resultatet i 2021, som var $-38.48M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Pharnext S.A. fra 2013 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-31.69M 1.28%
2023 $-31.29M -27.73%
2022 $-43.29M 12.50%
2021 $-38.48M 30.75%
2020 $-29.43M -0.92%
2019 $-29.70M 21.26%
2018 $-24.50M -15.52%
2017 $-29.00M 29.32%
2016 $-22.42M 87.83%
2015 $-11.94M -8.06%
2014 $-12.98M 1.29%
2013 $-12.82M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -16,747.05%
US
$1.95B -6,256.06%
NL
- -
CH
$3.01B -9,585.74%
BE
- -
KR